• Yih-Ting Chen, Heng-Chih Pan, Cheng-Kai Hsu, Chiao-Yin Sun, Chun-Yu Chen, Yi-Hung Chen, Heng-Jung Hsu, I-Wen Wu, Vin-Cent Wu, and Eric Hoste.
• Chang Gung University College of Medicine, Taoyuan, Taiwan.
• Crit Care. 2023 Aug 18; 27 (1): 318318.

BackgroundUrinary C-C motif chemokine ligand 14 (CCL14) has been described as an effective marker for delayed recovery of acute kidney injury (AKI), yet its efficacy has been found to vary between different trials. The goal of this research was to assess the predictive performance of urinary CCL14 as a marker for persistent AKI.MethodsIn accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched the PubMed, Embase, and Cochrane databases up to April 2023 for studies of adults (> 18 years) that reported the diagnostic performance of urinary CCL14. The sensitivity, specificity, number of events, true positive, and false positive results were extracted and evaluated. Hierarchical summary receiver operating characteristic curves (HSROCs) were used to summarize the pooled test performance, and the Grading of Recommendations, Assessment, Development and Evaluations criteria were used to appraise the quality of evidence.ResultsWe included six studies with 952 patients in this meta-analysis. The occurrence of persistent AKI among these patients was 39.6% (377/952). The pooled sensitivity and specificity results of urinary CCL14 in predicting persistent AKI were 0.81 (95% CI 0.72-0.87) and 0.71 (95% CI 0.53-0.84), respectively. The pooled positive likelihood ratio (LR) was 2.75 (95% CI 1.63-4.66), and the negative LR was 0.27 (95% CI 0.18-0.41). The HSROC with pooled diagnostic accuracy was 0.84.ConclusionOur results suggest that urinary CCL14 can be used as an effective marker for predicting persistent AKI.© 2023. BioMed Central Ltd., part of Springer Nature.

17 keywords...

hide…